Entera Bio (ENTX) Competitors $1.86 -0.23 (-11.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.86 0.00 (0.00%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. FULC, ITOS, RVNC, MBX, CKPT, RZLT, VIGL, SLDB, CMPX, and ADCTShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Fulcrum Therapeutics (FULC), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), MBX Biosciences (MBX), Checkpoint Therapeutics (CKPT), Rezolute (RZLT), Vigil Neuroscience (VIGL), Solid Biosciences (SLDB), Compass Therapeutics (CMPX), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Its Competitors Fulcrum Therapeutics iTeos Therapeutics Revance Therapeutics MBX Biosciences Checkpoint Therapeutics Rezolute Vigil Neuroscience Solid Biosciences Compass Therapeutics ADC Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability. Do analysts recommend FULC or ENTX? Fulcrum Therapeutics presently has a consensus target price of $6.29, indicating a potential downside of 8.24%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 437.63%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in FULC or ENTX? 89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 10.9% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, FULC or ENTX? Fulcrum Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Does the MarketBeat Community favor FULC or ENTX? Entera Bio received 78 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 67.67% of users gave Entera Bio an outperform vote while only 61.82% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes10261.82% Underperform Votes6338.18% Entera BioOutperform Votes18067.67% Underperform Votes8632.33% Does the media prefer FULC or ENTX? In the previous week, Fulcrum Therapeutics had 6 more articles in the media than Entera Bio. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 2 mentions for Entera Bio. Fulcrum Therapeutics' average media sentiment score of 1.13 beat Entera Bio's score of 0.43 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fulcrum Therapeutics Positive Entera Bio Neutral Is FULC or ENTX more profitable? Fulcrum Therapeutics' return on equity of -7.31% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Entera Bio N/A -107.24%-92.29% Which has higher earnings & valuation, FULC or ENTX? Entera Bio has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M4.62-$97.33M-$0.07-97.86Entera Bio$223K379.11-$8.89M-$0.26-7.15 SummaryFulcrum Therapeutics beats Entera Bio on 10 of the 18 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.54M$3.09B$5.57B$8.51BDividend YieldN/A1.56%5.27%4.16%P/E Ratio-7.1532.6326.7519.65Price / Sales379.11455.18404.17152.18Price / CashN/A168.6838.2534.64Price / Book5.173.366.964.59Net Income-$8.89M-$72.35M$3.23B$248.23M7 Day Performance-10.14%0.36%-1.22%-1.07%1 Month Performance-7.23%16.10%6.34%2.59%1 Year Performance-10.14%-15.37%33.05%13.50% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio1.8698 of 5 stars$1.86-11.0%$10.00+437.6%-10.1%$84.54M$223K-7.1520Short Interest ↑Gap UpFULCFulcrum Therapeutics0.4244 of 5 stars$7.12-1.8%$6.29-11.7%-8.1%$384.33M$80M-22.97100Positive NewsAnalyst RevisionGap DownITOSiTeos Therapeutics3.7346 of 5 stars$10.04-1.3%$15.86+57.9%-37.3%$384.27M$35M-3.1990Insider TradeRVNCRevance Therapeutics2.5647 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500MBXMBX Biosciences2.0119 of 5 stars$11.36-0.1%$37.50+230.1%N/A$379.70MN/A0.0036Gap UpCKPTCheckpoint Therapeutics2.509 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210RZLTRezolute2.6631 of 5 stars$4.31-2.7%$11.83+174.6%+6.3%$368.59MN/A-3.5340Positive NewsVIGLVigil Neuroscience4.0593 of 5 stars$7.88flat$10.80+37.1%+81.5%$367.78MN/A-3.8340High Trading VolumeSLDBSolid Biosciences3.8688 of 5 stars$4.62+1.8%$14.90+222.5%-42.9%$358.12M$8.09M-1.52100Positive NewsAnalyst RevisionGap DownCMPXCompass Therapeutics3.5636 of 5 stars$2.57+2.8%$13.13+410.7%+117.1%$355.39M$850K-6.9520Positive NewsADCTADC Therapeutics2.5872 of 5 stars$3.57-2.7%$7.75+117.1%+9.2%$354.07M$75.82M-1.49310News CoverageAnalyst ForecastAnalyst RevisionGap Down Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors iTeos Therapeutics Competitors Revance Therapeutics Competitors MBX Biosciences Competitors Checkpoint Therapeutics Competitors Rezolute Competitors Vigil Neuroscience Competitors Solid Biosciences Competitors Compass Therapeutics Competitors ADC Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENTX Stock Free ENTX Stock Alerts